Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
about
Pro-urokinase-type plasminogen activator is a substrate for hepsinUrokinase, a constitutive component of the inflamed synovial fluid, induces arthritisSuppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascadeEpidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.Proliferation and invasion: plasticity in tumor cells.Ets target genes: past, present and future.Principles of liver regeneration and growth homeostasis.Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.Sequential activation of ERK and repression of JNK by scatter factor/hepatocyte growth factor in madin-darby canine kidney epithelial cellsActivation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy.The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.Plasmin-mediated proteolysis is required for hepatocyte growth factor activation during liver repair.{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoterInhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro.Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways.Low molecular weight protein-tyrosine phosphatase controls the rate and the strength of NIH-3T3 cells adhesion through its phosphorylation on tyrosine 131 or 132.Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells.Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent.Age-related changes in the mitotic and metabolic characteristics of muscle-derived cells.[Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
P2860
Q24299743-0ABF8369-6CD8-4955-B5C4-E22DC8E6C065Q24795914-F31543DF-006B-494D-A8D8-0ED3F2BDCA58Q28218095-C1D28EEF-3237-4802-8055-8F6A4C1E48CCQ30450853-69A4407C-EA2F-45F6-8564-D638BB6B17CFQ33906737-9257948C-4848-4539-AF58-2A1E59F9F2C8Q33933227-1C21C7EF-A974-495D-8608-85E15A7AD0E4Q34347580-E744A3F7-1A55-47EB-90BE-0B27EB9BDB08Q34606581-D02D5BC4-24DB-45E5-942C-42D426D21080Q34775192-AF4B38E4-2CB7-4480-A46C-1DAF848605DDQ34785157-616E7BCE-DEA0-4AE1-8DAE-CE09B2F9F755Q35595625-91877CF4-A739-4B3B-9D7A-52116E13F7A8Q36494563-994AFCA7-D0F9-4D5D-8B9D-19ED1B668848Q37176420-D27129BB-C346-4C55-A728-23C8FBDBA06CQ37413723-78A5115A-A745-4903-8D87-E15FD1489694Q39458488-505DCF64-6164-4742-9153-9C8568CF8998Q39701679-218E39F7-74E0-40FD-8A9D-FF7B6D6657B7Q40431244-42EC0F62-EBF1-4B18-9000-8CDB631C4866Q40694018-99A67DAA-E640-48DE-B5A2-443F62CFAB89Q40749632-CC134798-8393-42BC-977E-16F936EFC8CCQ40846518-29B91585-8D1F-4074-AAB7-B11A41AE463FQ42797569-0A383505-DE36-41C3-8602-58CF59263217Q43594124-180D96F7-BDB6-4B82-91A7-26D4A2E33C3FQ43597895-4A9ADF75-497B-49CD-B784-94790462A802Q43862137-A5906E9C-F35E-447A-B455-A34CD45B0322Q44615189-38F9764A-3D62-40A8-BE40-F238A7CF5A79Q53232399-23BE2C43-151E-4AAD-BA39-1C09C63E6824Q53525637-90412198-F32B-453F-9B15-4F8E0ABF628CQ55230617-8659072C-8644-4657-B567-4E5A78B7FE65
P2860
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Activation mechanisms of the u ...... growth factor/scatter factor.
@en
type
label
Activation mechanisms of the u ...... growth factor/scatter factor.
@en
prefLabel
Activation mechanisms of the u ...... growth factor/scatter factor.
@en
P2093
P2860
P356
P1476
Activation mechanisms of the u ...... growth factor/scatter factor.
@en
P2093
Vande Woude GF
P2860
P304
16377-16386
P356
10.1074/JBC.274.23.16377
P407
P577
1999-06-01T00:00:00Z